Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
China Approves Monthly IV Maintenance Dosing of Leqembi
China’s health regulators have approved the monthly intravenous maintenance dosing of Alzheimer’s disease (AD) therapy Leqembi (lecanemab), Eisai and Biogen said on September 29. The drug is indicated for the treatment of AD in patients with mild cognitive impairment (MCI)…
To read the full story
Related Article
- Eisai’s Leqembi Added to China Commercial Insurance Drug List
December 10, 2025
- Eisai’s Alzheimer’s Med Leqembi Now Available in China
July 1, 2024
BUSINESS
- Otsuka to Acquire Transcend for US$700 Million, Snags PTSD Candidate
March 30, 2026
- Eisai, MSD File Lenvima-Welireg Combo in Japan for RCC
March 30, 2026
- Chugai CEO Takes Home 441 Million Yen in 2025: Securities Report
March 30, 2026
- Takeda to Resume MR Vaccine Shipments in June after Potency Issue
March 30, 2026
- Kyowa Kirin’s Mullick Earns 263 Million Yen in 2025; Workforce Down Sharply
March 30, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…